Article
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
Blood advances - 14 Sept 2021
van der Werf Inge, Wojtuszkiewicz Anna, Meggendorfer Manja, Hutter Stephan, Baer Constance, Heymans Martijn, Valk Peter J M, Kern Wolfgang, Haferlach Claudia, Janssen Jeroen J W M, Ossenkoppele Gert J, Cloos Jacqueline, Haferlach Torsten
Abstract excerpt
Splicing factor (SF) mutations are important contributors to the pathogenesis of hematological malignancies; however, their relevance in risk classification of acute myeloid leukemia (AML) warrants further investigation. To gain more insight into the characteristics of patients with AML carrying SF mutations, we studied their association with clinical features, cytogenetic and molecular abnormalities, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.